• Explore /
  • Poster
  • / Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m<sup>2</sup> and once-weekly at 70 mg/m<sup>2 </sup>in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.

Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.

Abstract Video & Slides Poster

Authors

null

Xavier Leleu

Hopital Claude Huriez, Lille, France

Xavier Leleu , Meral Beksac , Takaaki Chou , Meletios A. Dimopoulos , Sung-Soo Yoon , H. Miles Prince , Ludek Pour , Tatiana Shelekhova , Ajai Chari , Monica Khurana , Mihaela Obreja , Ming Qi , Albert Oriol , David Samuel DiCapua Siegel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT03158688

Citation

J Clin Oncol 38: 2020 (suppl; abstr 8526)

DOI

10.1200/JCO.2020.38.15_suppl.8526

Abstract #

8526

Poster Bd #

426

Abstract Disclosures

Similar Posters

First Author: Maria-Victoria Mateos

First Author: Cyrille Touzeau

First Author: Robert Z. Orlowski

First Author: Pieter Sonneveld